Table 4.
Therapies targeting IL-1RAP that underwent clinical trials.
| Anti-IL-1RAP Treatment | Treatment in Combination | Clinical Phase | Pathology | CURRENT STATUS | ClinicalTrial ID (Study Name) |
|---|---|---|---|---|---|
| Full antibody (Nadunolimab) | Cisplatin Gemcitabine Nab-paclitaxel |
I/IIa | PDAC (phase I/IIa) NSCLC (phase I/IIa) TNBC (phase I) CRC (phase I) |
Phase I: Completed Phase IIa: Active, not recruiting (PDAC) Recruiting (NSCLC) |
NCT03267316 (CANFOUR) [26,150,151] |
| Full antibody (Nadunolimab) | Pembrolizumab | I | NSCLC UC HNSCC Malignant Melanoma |
Active, not recruiting | NCT04452214 (CIRIFOUR) |
| Full antibody (Nadunolimab) | FOLFIRINOX | I | Metastatic PDAC | Active, not recruiting | NCT04990037 (CAPAFOUR) |
| Full antibody (Nadunolimab) | mFOLFOX DTX G/C |
I/II | Advanced solid tumors CRC NSCLC BTC |
Active, not recruiting | NCT05116891 (CESTAFOUR) |
| Full antibody (Nadunolimab) | Carboplatin Gemcitabine |
I/II | TNBC | Recruiting | NCT05181462 (TRIFOUR) |
| CAR-T cells | None | N/A | CML | Completed |
NCT02842320 (CAR-LMC) |
| CAR-T cells | None | N/A | AML | Recruiting |
NCT04169022 (CAR-LAM) |
Abbreviations: AML: acute myeloid leukemia; BTC: biliary tract cancer; CAR: chimeric antigen receptor; CML: chronic myeloblastic leukemia; CRC: colorectal cancer; DTX: docetaxel; FOLFIRINOX: folinic acid, fluorouracil, irinotecan, oxaliplatin; G/C: gemcitabine/cisplatin; HNSCC: head and neck squamous cell carcinoma; ID: identifier; mFOLFOX: modified FOLFOX (Oxaliplatin, 5-fluorouracil, leucovorin); N/A: not applicable; NSCLC: non-small cell lung cancer; PDAC: pancreatic ductal adenocarcinoma; TNBC: triple-negative breast cancer; UC: urothelial carcinoma.